Navigation Links
Intra-Cellular Therapies Announces Closing of $60 Million Private Placement and Completion of Reverse Merger
Date:9/3/2013

Shortly after the closing of these transactions, the resulting public company will have the same shareholders, officers and directors as did ITI prior to the reverse merger.

In connection with the private placement, ITI has agreed, subject to certain terms and conditions, to file a registration statement under the Securities Act of 1933, as amended, covering the resale of shares of common stock held by new and existing shareholders within 45 days after the closing. Following the effectiveness of that registration statement, we plan to seek to have our common stock quoted on the OTC Markets. The shares of common stock issued and sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from the registration requirements.  Following the effectiveness of this registration statement, we plan to seek to have our common stock quoted on the OTC Markets.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

ABOUT ITI-007

ITI-007 is the Company's lead drug development candidate, whose unique mechanisms of action have the potential to yield a first-in-class antipsychotic therapy. ITI-007 combines potent serotonin 5-HT2A receptor antagonism, dopamine receptor phosphoprotein modulation (DPPM), glutamatergic modulation and serotonin reuptake inhibition into a single drug candidate for the treatment of acute and residual schizophrenia.  At dopamine D2 receptors, ITI-007 has dual properties and acts as both a post-synaptic antagonis
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
2. Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
3. The Dyslipidemia Market Will Grow to $31 Billion in 2022, Driven by the Launch of Novel Therapies
4. Up to Sixty Percent of Surveyed U.S. Managed Care Organization Directors Expect to Cover Key Emerging Therapies for Parkinsons Disease on Their Largest Commercial Plan
5. CSL Biotherapies initiates shipments of its seasonal influenza vaccine to U.S. customers
6. MCOs Shifting Control Over Office-Administered Products from Medical to Pharmacy Benefit, Particularly Affecting Rheumatoid Arthritis Therapies
7. The Launch of Three New Parkinsons Disease Therapies Through 2015 Will Help Offset Market Losses Resulting from the Growing Impact of Generics
8. Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share
9. NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity
10. In Terms of Effect on Overall Survival, Current and Emerging Therapies Have No Advantage Over Avastin/FOLFIRI in the Treatment of Second-Line Metastatic Colorectal Cancer, According to Clinical Data and Thought Leader Opinion
11. Tafinlar in Combination with Mekinist and Nivolumab Have Considerable Efficacy and Tolerability Advantages Over Currently Used Therapies for the Treatment of Unresectable Malignant Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Hologic, Inc. (NASDAQ: ... and Chief Executive Officer, will present at the Morgan Stanley ... , New York on Tuesday, September ... parties are invited to listen to the live audio webcast ... at www.hologic.com/investors-overview . An archive of the presentation will ...
(Date:9/2/2014)... SEATTLE , Sept. 2, 2014 /PRNewswire/ ... company committed to the development and commercialization ... today announced an update on corporate and ... structure, commitment for future funding, ongoing clinical ... In corporate news, Chief Executive Officer ...
(Date:9/2/2014)...  BioSpecifics Technologies Corp. (NASDAQ: BSTC ), a ... XIAFLEX ® in the U.S. and XIAPEX ® ... Wegman , will present at the following upcoming investor conferences. ... & Renshaw 16 th Annual Global Investment Conference ... 9, 2014 at 9:10 a.m. EDT , Aegis ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Provides Corporate and Clinical Update 2VentiRx Pharmaceuticals Provides Corporate and Clinical Update 3BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences 2
... (NASDAQ: AMRI ), a global contract services organization ... as part of its ongoing global operations review to improve ... its European operations focused on a reduction of the workforce ... at its Budapest, Hungary operation. As a ...
... Jan. 9, 2012  Xenon today announced a strategic alliance ... RO, ROG; OTCQX: RHHBY), to discover and develop compounds ... "We are delighted to be collaborating with ... "Genentech is among the world,s leading biotech companies and ...
Cached Medicine Technology:AMRI Announces Review of Its Hungary Operation 2AMRI Announces Review of Its Hungary Operation 3Xenon to Collaborate with Genentech on Discovery of Novel Targeted Pain Therapeutics 2
(Date:9/2/2014)... September 02, 2014 The new ... to reduce discomfort and fatigue by absorbing stress and ... eco-friendly, renewable bio-foam core, these anti-fatigue mats are intended ... According to a study by the Texas A&M University, ... difference in reducing spinal compression and increase in sit-reach ...
(Date:9/2/2014)... A little white pill may help scientists learn why ... their peers, even if their lungs are relatively healthy. ... marketed as Revatio to treat pulmonary hypertension and Viagra ... of over-the-counter antioxidants will help them identify the root ... for these patients. , "We want to understand ...
(Date:9/2/2014)... increasing concern to health officials both in NYC and ... Health and Mental Hygiene, the number of unintentional opioid-involved ... of such deaths in 2000. Much of the increase ... prescription opioid (PO) use among teens and young adults, ... transitioned from POs to heroin. , Now researchers ...
(Date:9/2/2014)... new guideline, the Society for Maternal-Fetal Medicine has recommended ... , "There is no evidence that bed rest ... Center for Maternal and Fetal Medicine and one of ... that bed rest can be harmful for moms, babies, ... are placed on bed rest during their pregnancy. Surveys ...
(Date:9/2/2014)... -- Many people believe that marijuana is not addictive, ... more people are able to obtain and consume cannabis ... people are less likely to perceive it as addictive ... Massachusetts General Hospital,s Center for Addiction Medicine, said in ... cannabis use can have significant consequences, and we know ...
Breaking Medicine News(10 mins):Health News:New Eco-Pro Premium Anti-fatigue Mats from Martinson-Nicholls Prevent Fatigue and Discomfort for Standing Workers 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 3Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 4Health News:NYC teens and young adults who abuse prescription at high risk for overdose 2Health News:NYC teens and young adults who abuse prescription at high risk for overdose 3Health News:SMFM releases paper on activity restriction in pregnancy 2Health News:'Pot Addiction' May Be Real, Study Suggests 2
... Alan Mozes HealthDay Reporter , WEDNESDAY, July 20 ... shorter people to develop cancer, new British research says. ... cancer, leukemia or melanoma appears to go up about 16 ... "Taller women in our study had increased risk of ...
... Neurologist Michele Tagliati, MD, director of the Movement ... an elite international task force commissioned by the ... on deep brain stimulation for dystonia, an uncommon ... The resulting articles, describing the data ...
... , WEDNESDAY, July 20 (HealthDay News) -- In a ... Wednesday approved the blood thinner Brilinta (ticagrelor) for use ... their odds for heart attack and death. Acute ... or heart attack linked to lowered blood flow to ...
... HealthDay Reporter , WEDNESDAY, July 20 (HealthDay News) -- ... disease as a major health threat, fearing its onset nearly ... Germany, Poland, Spain and the United States, the poll also ... to visit a doctor if they or a loved one ...
... Reporter , WEDNESDAY, July 20 (HealthDay News) -- The race ... New technology promises to cut costs while speeding the amount ... and potentially provide a personalized report of health risks and ... was first mapped in 2001 and cost roughly $1 billion ...
... (HealthDay News) --, Liars can control certain facial expressions when ... time, a new study shows. The researchers noted the ... conducting the study, scientists randomly asked 60 people to either ... pair of movie tickets from an envelope. While being interviewed, ...
Cached Medicine News:Health News:Study Contends Taller People at Heightened Cancer Risk 2Health News:Study Contends Taller People at Heightened Cancer Risk 3Health News:Cedars-Sinai movement disorders expert on international task force for dystonia treatment 2Health News:Cedars-Sinai movement disorders expert on international task force for dystonia treatment 3Health News:Cedars-Sinai movement disorders expert on international task force for dystonia treatment 4Health News:FDA Approves Blood Thinner Brilinta for Heart Patients 2Health News:International Poll Shows Many Fear Alzheimer's as Much as Cancer 2Health News:International Poll Shows Many Fear Alzheimer's as Much as Cancer 3Health News:Cheaper DNA Sequencing Coming Closer 2Health News:Cheaper DNA Sequencing Coming Closer 3Health News:Scrutinizing Faces Might Catch Liars, Study Finds 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: